JNJ-17000139, JNJ-63723283, JNJ-63723283
17000139BLC2002
Phase 2 small_molecule active
Quick answer
JNJ-17000139, JNJ-63723283, JNJ-63723283 for Muscle-Invasive Urothelial Carcinoma of the Bladder is a Phase 2 program (small_molecule) at Janssen-Cilag International N.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Janssen-Cilag International N.V.
- Indication
- Muscle-Invasive Urothelial Carcinoma of the Bladder
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active